Bridging the gap: academia, industry and FDA convergence for nanomaterials
Nano-medicine is the fastest growing field in pharmaceutical industry today. However, there still exist several hurdles preceding its clinical translation. This review provides insights on the guidelines for nanomaterials provided by the US-FDA (United States Food and Drug Administration), various a...
Gespeichert in:
| Veröffentlicht in: | Drug development and industrial pharmacy 2020-11, Vol.46 (11), p.1735-1746 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1746 |
|---|---|
| container_issue | 11 |
| container_start_page | 1735 |
| container_title | Drug development and industrial pharmacy |
| container_volume | 46 |
| creator | Shah, Saurabh Nene, Shweta Rangaraj, Nagarjun Raghuvanshi, Rajeev Singh Singh, Shashi Bala Srivastava, Saurabh |
| description | Nano-medicine is the fastest growing field in pharmaceutical industry today. However, there still exist several hurdles preceding its clinical translation. This review provides insights on the guidelines for nanomaterials provided by the US-FDA (United States Food and Drug Administration), various approval pathways and also addresses the lacunae between academic research, pharmaceutical industry and US-FDA through an attempt to overcome the hurdle to its clinical translation. We have also emphasized various ways to overcome the described barriers which will provide the readers a brief understanding over the critical aspects where the scope of the guidelines may need to be revisited in order to exhibit their successful clinical translation from academic research to commercial feasibility. |
| doi_str_mv | 10.1080/03639045.2020.1821055 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_03639045_2020_1821055</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32901536</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-35569b8f65ed784fffa2a5dbce3ac62ab70e1054dcd0b1d1e1dffeb25128c3403</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwCSB_ACl-xG7CilIoD1ViA2tr4kcwapzKSUH5exK1ZcnqSqNzZzQHoUtKppRk5IZwyXOSiikjrB9ljBIhjtCYCkYSMZPsGI0HJhmgETprmi9CKMuFOEUjznJCBZdj9HofvSl9KHH7aXEJm1sMGoytPFxjH8y2aWOHIRi8fJhjXYdvG0sbtMWujjhAqCtobfSwbs7RievDXuxzgj6Wj--L52T19vSymK8SzaVsEy6EzIvMSWHNLEudc8BAmEJbDloyKGbE9r-kRhtSUEMtNc7ZggnKMs1TwidI7PbqWDdNtE5toq8gdooSNbhRBzdqcKP2bvre1a632RaVNX-tg4weuNsBPvTPVfBTx7VRLXTrOroIQftG8f9v_AKR-nOB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Bridging the gap: academia, industry and FDA convergence for nanomaterials</title><source>MEDLINE</source><source>EBSCOhost Business Source Complete</source><creator>Shah, Saurabh ; Nene, Shweta ; Rangaraj, Nagarjun ; Raghuvanshi, Rajeev Singh ; Singh, Shashi Bala ; Srivastava, Saurabh</creator><creatorcontrib>Shah, Saurabh ; Nene, Shweta ; Rangaraj, Nagarjun ; Raghuvanshi, Rajeev Singh ; Singh, Shashi Bala ; Srivastava, Saurabh</creatorcontrib><description>Nano-medicine is the fastest growing field in pharmaceutical industry today. However, there still exist several hurdles preceding its clinical translation. This review provides insights on the guidelines for nanomaterials provided by the US-FDA (United States Food and Drug Administration), various approval pathways and also addresses the lacunae between academic research, pharmaceutical industry and US-FDA through an attempt to overcome the hurdle to its clinical translation. We have also emphasized various ways to overcome the described barriers which will provide the readers a brief understanding over the critical aspects where the scope of the guidelines may need to be revisited in order to exhibit their successful clinical translation from academic research to commercial feasibility.</description><identifier>ISSN: 0363-9045</identifier><identifier>EISSN: 1520-5762</identifier><identifier>DOI: 10.1080/03639045.2020.1821055</identifier><identifier>PMID: 32901536</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Clinical translation ; convergence ; Drug Approval ; Drug Industry ; harmonization ; nanomaterials ; Nanostructures ; Pharmaceutical Preparations ; regulatory aspects ; United States ; United States Food and Drug Administration</subject><ispartof>Drug development and industrial pharmacy, 2020-11, Vol.46 (11), p.1735-1746</ispartof><rights>2020 Informa UK Limited, trading as Taylor & Francis Group 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-35569b8f65ed784fffa2a5dbce3ac62ab70e1054dcd0b1d1e1dffeb25128c3403</citedby><cites>FETCH-LOGICAL-c366t-35569b8f65ed784fffa2a5dbce3ac62ab70e1054dcd0b1d1e1dffeb25128c3403</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32901536$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shah, Saurabh</creatorcontrib><creatorcontrib>Nene, Shweta</creatorcontrib><creatorcontrib>Rangaraj, Nagarjun</creatorcontrib><creatorcontrib>Raghuvanshi, Rajeev Singh</creatorcontrib><creatorcontrib>Singh, Shashi Bala</creatorcontrib><creatorcontrib>Srivastava, Saurabh</creatorcontrib><title>Bridging the gap: academia, industry and FDA convergence for nanomaterials</title><title>Drug development and industrial pharmacy</title><addtitle>Drug Dev Ind Pharm</addtitle><description>Nano-medicine is the fastest growing field in pharmaceutical industry today. However, there still exist several hurdles preceding its clinical translation. This review provides insights on the guidelines for nanomaterials provided by the US-FDA (United States Food and Drug Administration), various approval pathways and also addresses the lacunae between academic research, pharmaceutical industry and US-FDA through an attempt to overcome the hurdle to its clinical translation. We have also emphasized various ways to overcome the described barriers which will provide the readers a brief understanding over the critical aspects where the scope of the guidelines may need to be revisited in order to exhibit their successful clinical translation from academic research to commercial feasibility.</description><subject>Clinical translation</subject><subject>convergence</subject><subject>Drug Approval</subject><subject>Drug Industry</subject><subject>harmonization</subject><subject>nanomaterials</subject><subject>Nanostructures</subject><subject>Pharmaceutical Preparations</subject><subject>regulatory aspects</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>0363-9045</issn><issn>1520-5762</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EoqXwCSB_ACl-xG7CilIoD1ViA2tr4kcwapzKSUH5exK1ZcnqSqNzZzQHoUtKppRk5IZwyXOSiikjrB9ljBIhjtCYCkYSMZPsGI0HJhmgETprmi9CKMuFOEUjznJCBZdj9HofvSl9KHH7aXEJm1sMGoytPFxjH8y2aWOHIRi8fJhjXYdvG0sbtMWujjhAqCtobfSwbs7RievDXuxzgj6Wj--L52T19vSymK8SzaVsEy6EzIvMSWHNLEudc8BAmEJbDloyKGbE9r-kRhtSUEMtNc7ZggnKMs1TwidI7PbqWDdNtE5toq8gdooSNbhRBzdqcKP2bvre1a632RaVNX-tg4weuNsBPvTPVfBTx7VRLXTrOroIQftG8f9v_AKR-nOB</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Shah, Saurabh</creator><creator>Nene, Shweta</creator><creator>Rangaraj, Nagarjun</creator><creator>Raghuvanshi, Rajeev Singh</creator><creator>Singh, Shashi Bala</creator><creator>Srivastava, Saurabh</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20201101</creationdate><title>Bridging the gap: academia, industry and FDA convergence for nanomaterials</title><author>Shah, Saurabh ; Nene, Shweta ; Rangaraj, Nagarjun ; Raghuvanshi, Rajeev Singh ; Singh, Shashi Bala ; Srivastava, Saurabh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-35569b8f65ed784fffa2a5dbce3ac62ab70e1054dcd0b1d1e1dffeb25128c3403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Clinical translation</topic><topic>convergence</topic><topic>Drug Approval</topic><topic>Drug Industry</topic><topic>harmonization</topic><topic>nanomaterials</topic><topic>Nanostructures</topic><topic>Pharmaceutical Preparations</topic><topic>regulatory aspects</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shah, Saurabh</creatorcontrib><creatorcontrib>Nene, Shweta</creatorcontrib><creatorcontrib>Rangaraj, Nagarjun</creatorcontrib><creatorcontrib>Raghuvanshi, Rajeev Singh</creatorcontrib><creatorcontrib>Singh, Shashi Bala</creatorcontrib><creatorcontrib>Srivastava, Saurabh</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Drug development and industrial pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shah, Saurabh</au><au>Nene, Shweta</au><au>Rangaraj, Nagarjun</au><au>Raghuvanshi, Rajeev Singh</au><au>Singh, Shashi Bala</au><au>Srivastava, Saurabh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bridging the gap: academia, industry and FDA convergence for nanomaterials</atitle><jtitle>Drug development and industrial pharmacy</jtitle><addtitle>Drug Dev Ind Pharm</addtitle><date>2020-11-01</date><risdate>2020</risdate><volume>46</volume><issue>11</issue><spage>1735</spage><epage>1746</epage><pages>1735-1746</pages><issn>0363-9045</issn><eissn>1520-5762</eissn><abstract>Nano-medicine is the fastest growing field in pharmaceutical industry today. However, there still exist several hurdles preceding its clinical translation. This review provides insights on the guidelines for nanomaterials provided by the US-FDA (United States Food and Drug Administration), various approval pathways and also addresses the lacunae between academic research, pharmaceutical industry and US-FDA through an attempt to overcome the hurdle to its clinical translation. We have also emphasized various ways to overcome the described barriers which will provide the readers a brief understanding over the critical aspects where the scope of the guidelines may need to be revisited in order to exhibit their successful clinical translation from academic research to commercial feasibility.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>32901536</pmid><doi>10.1080/03639045.2020.1821055</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0363-9045 |
| ispartof | Drug development and industrial pharmacy, 2020-11, Vol.46 (11), p.1735-1746 |
| issn | 0363-9045 1520-5762 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_03639045_2020_1821055 |
| source | MEDLINE; EBSCOhost Business Source Complete |
| subjects | Clinical translation convergence Drug Approval Drug Industry harmonization nanomaterials Nanostructures Pharmaceutical Preparations regulatory aspects United States United States Food and Drug Administration |
| title | Bridging the gap: academia, industry and FDA convergence for nanomaterials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T11%3A13%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bridging%20the%20gap:%20academia,%20industry%20and%20FDA%20convergence%20for%20nanomaterials&rft.jtitle=Drug%20development%20and%20industrial%20pharmacy&rft.au=Shah,%20Saurabh&rft.date=2020-11-01&rft.volume=46&rft.issue=11&rft.spage=1735&rft.epage=1746&rft.pages=1735-1746&rft.issn=0363-9045&rft.eissn=1520-5762&rft_id=info:doi/10.1080/03639045.2020.1821055&rft_dat=%3Cpubmed_cross%3E32901536%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32901536&rfr_iscdi=true |